First FDA authorization for next-generation sequencer

Affiliations

¹ From the Office of the Director, National Institutes of Health, Bethesda, MD (F.S.C.); and the Office of the Commissioner, Food and Drug Administration, Department of Health and Human Services, Silver Spring, MD (M.A.H.).

Francis S Collins et al. N Engl J Med. 2013.

. 2013 Dec 19;369(25):2369-71.

doi: 10.1056/NEJMp1314561. Epub 2013 Nov 19.

¹ From the Office of the Director, National Institutes of Health, Bethesda, MD (F.S.C.); and the Office of the Commissioner, Food and Drug Administration, Department of Health and Human Services, Silver Spring, MD (M.A.H.).

No abstract available

Figures

1. Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013;502:333–9. - PMC - PubMed
1. Table of pharmacogenomic biomarkers in drug labeling. Silver Spring, MD: Food and Drug Administration; 2013. ( http://www.fda.gov/%20drugs/scienceresearch/researchareas/pharmacogeneti...)
1. Furie B. Do pharmacogenetics have a role in the dosing of vitamin K antagonists? N Engl J Med. 2013;369:2345–6. - PubMed
1. Hudson KL. Genomics, health care, and society. N Engl J Med. 2011;365:1033–41. - PubMed
1. Paving the way for personalized medicine: FDA’s role in a new era of medical product development. Silver Spring, MD: Food and Drug Administration; Oct, 2013. ( http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/PersonalizedM...)